CytomX

$7.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.33 (+4.89%) As of 4:58 PM UTC today

Why Robinhood?

You can buy or sell CytomX and other stocks, options, and ETFs commission-free!

About CTMX

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs.

CEO

Sean A. McCarthy

Employees

146

Headquarters

South San Francisco, California

Founded

2010

Market Cap

537.77M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

979.02K

High Today

$7.23

Low Today

$6.85

Open Price

$6.85

Volume

649.02K

52 Week High

$15.44

52 Week Low

$6.25

Analyst Ratings

73%

of 11 ratings

Buy

73%

Hold

27%

Sell

CTMX Earnings

-$0.79

-$0.44

-$0.09

$0.26

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Estimated

— per share

Actual

Expected May 6, After Hours